SCHEMBL15215650

SCHEMBL15215650

CC(=O)C1(c2ccccc2)CC(=O)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C1 Q04828 1/20 0.48
HDAC9 Q9UKV0 1/20 0.46
HDAC4 P56524 3/20 0.44
OPRM1 P35372 4/20 0.42
HSD11B1 P28845 2/20 0.42
OPRL1 P41146 1/20 0.42
ALOX15 P16050 1/20 0.41
OPRD1 P41143 3/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CYP2C9 P11712 1/20 0.41
P2RX7 Q99572 1/20 0.41
ALDH1A1 P00352 1/20 0.39
OPRK1 P41145 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17327809 0.86 HDAC9 (0.62) AKR1C1HDAC9HDAC4OPRM1HSD11B1
SCHEMBL890180 0.83 AKR1C1 (0.57) AKR1C1HDAC9HDAC4OPRM1HSD11B1
SCHEMBL8106838 0.83 AKR1C1 (0.63) AKR1C1HDAC9HDAC4HSD11B1ALOX15
SCHEMBL1447883 0.82 MEN1 (0.55) AKR1C1HDAC4OPRM1HSD11B1OPRL1
SCHEMBL28304679 0.79 AKR1C1 (0.48) AKR1C1HDAC9HDAC4OPRM1HSD11B1
SCHEMBL3737199 0.79 AKR1C1 (0.70) AKR1C1HDAC4HSD11B1OPRD1CA12
SCHEMBL12928712 0.79 AKR1C1 (0.64) AKR1C1HDAC4HSD11B1OPRD1CA12
SCHEMBL25463734 0.78 OPRM1 (0.47) AKR1C1HDAC9HDAC4OPRM1HSD11B1
SCHEMBL1838291 0.78 AKR1C1 (0.68) AKR1C1HDAC4HSD11B1MEN1KMT2A
SCHEMBL24663621 0.78 AKR1C1 (0.52) AKR1C1HDAC9HDAC4OPRM1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130225615-A1 2-CYCLOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225615-A1 2-CYCLOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF JAK2, JAK3, TYK2 AKR1C1 4664/4885HDAC9 1492/4885HDAC4 2071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.